Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

240.04 +1.71 (+0.72%)

Streaming Delayed Price Updated: 12:17 PM EDT, Jun 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Johnson & Johnson Q1 2026 Earnings Call Transcript ↗

April 14, 2026

Johnson & Johnson (NASDAQ: JNJ) reported first-quarter financial results on Tuesday. The transcript from the company's first-quarter earnings call has been provided below.

Via Benzinga

Topics Earnings

Johnson & Johnson Shatters Expectations in Q1 2026, Raising Full-Year Outlook as Healthcare Giant Pushes Toward $100 Billion Milestone

April 14, 2026

NEW BRUNSWICK, N.J. — In a powerful display of resilience and strategic execution, Johnson & Johnson (NYSE: JNJ) reported first-quarter 2026 financial results that exceeded Wall Street estimates across...

Via MarketMinute

Topics Economy Intellectual Property

Johnson & Johnson Q1 Performance: Cancer Drug Revenue Grows, Free Cash Flow Falls, Hikes Dividend ↗

April 14, 2026

Johnson & Johnson Q1 pharma growth offsets immunology decline; company raises guidance and extends dividend streak.

Via Benzinga

The New J&J: A 2026 Deep Dive into the Global Healthcare Titan

April 14, 2026

As of April 14, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different entity than it was only three years ago. Following the successful spin-off of its consumer health division, Kenvue,...

Via Finterra

Topics Artificial Intelligence Death Economy

Dow Jones' J&J Slips Despite Beating First-Quarter Calls, Hiking Guidance ↗

April 14, 2026

Johnson & Johnson stock fell early Tuesday despite better-than-expected first-quarter sales and earnings, and a guidance hike.

Via Investor's Business Daily

Topics Stocks

Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

April 14, 2026

From Johnson & Johnson

Via Business Wire

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

April 14, 2026

From Johnson & Johnson

Via Business Wire

Dow Jones Stocks In Spotlight: JPMorgan, Johnson & Johnson Among This Week's Earnings Reports ↗

April 13, 2026

Four of the 30 Dow Jones Industrial Average stocks report this week. Here's a look at the companies and what the key figures to watch are.

Via Benzinga

Topics Stocks

Is This Dividend King With a 63-Year Dividend Streak A Buy Before April 14?

April 13, 2026

This Dividend King offers a rare mix of safety and upside heading into earnings.

Via Barchart.com

Which Dividend Pharma Stock Should a Value Investor Choose Today? ↗

April 12, 2026

Bristol Myers Squibb looks like a value buy, so long as its pipeline remains strong.

Via The Motley Fool

Topics Intellectual Property

Nvidia Built an AI Chip Empire. But It's This Other Creation That Makes the Stock a Screaming Buy Today. ↗

April 12, 2026

The future looks bright for this AI star.

Via The Motley Fool

Topics Artificial Intelligence

History Says the Best Time to Buy Stocks May Be Imminent ↗

April 12, 2026

The best time to buy stocks may be closer than you think -- and history has the receipts.

Via The Motley Fool

Topics Government Stocks World Trade

Better Buy Right Now: Johnson & Johnson Vs. Pfizer ↗

April 12, 2026

The choice is based on more than just the dividend payout.

Via The Motley Fool

Topics Artificial Intelligence

Smooth Investing When the Ride Is Bumpy ↗

April 11, 2026

Diversification is a winning strategy for the long term, especially in a volatile market.

Via The Motley Fool

The $100 Billion Pivot: Why Johnson & Johnson Is My Top Dividend King to Buy in 2026 ↗

April 11, 2026

This stock might help you sleep more easily at night.

Via The Motley Fool

Topics Economy Intellectual Property Lawsuit

4 Stocks That Can Fund Decades of Passive Income -- Buy Them While They're Down ↗

April 11, 2026

These defensive consumer stocks are flashing buy signals while the market chases AI hype.

Via The Motley Fool

Topics Artificial Intelligence

Stocks Rallied After President Donald Trump's Ceasefire in Iran. Here's How to Invest Now. ↗

April 11, 2026

Moves made now could position your portfolio for success over time.

Via The Motley Fool

Topics Government Stocks

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

April 10, 2026

From Johnson & Johnson

Via Business Wire

Could Buying This Dividend Pharma Stock Today Set You Up for Life? ↗

April 09, 2026

This Dividend King drug maker's dividend yield is roughly twice that of the S&P 500 index.

Via The Motley Fool

Topics Stocks

Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value

April 09, 2026

Via Investor Brand Network

Topics Artificial Intelligence

The Teleflex Pivot: Inside the $1 Billion Share Buyback and Strategic Breakup

April 09, 2026

Disclaimer: This content is intended for informational purposes only and is not financial advice. Today’s date is April 9, 2026. Introduction In the high-stakes arena of medical technology, few stories...

Via Finterra

Topics Economy World Trade

ImmunityBio (IBRX): From R&D Speculation to Record Commercial Revenue

April 09, 2026

Today's Date: April 9, 2026 Introduction In the high-stakes arena of biotechnology, few companies have undergone a transformation as dramatic as ImmunityBio, Inc. (NASDAQ: IBRX). Long viewed by Wall...

Via Finterra

Topics Economy World Trade

Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value

April 09, 2026

From AINewsWire

Via GlobeNewswire

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

April 09, 2026

JNJ (NYSE: JNJ) to release Q1 earnings before bell on April 14. Analysts expect $2.67/share & $23.6B revenue. FDA approves TECNIS PureSee lens.

Via Benzinga

These 3 Beaten-Down Stocks Haven't Been This Cheap in Over a Decade ↗

April 08, 2026

Buying stocks at incredibly low valuations often comes with risk, but it may also result in massive returns.

Via The Motley Fool

Topics Economy World Trade

This Healthcare Stock Has No Debt and a Near-Monopoly in Its Market ↗

April 07, 2026

The company is a picture of financial stability.

Via The Motley Fool

Martin Capital Dumps $4.5 Million in Robert Half Shares After a Brutal Year for the Staffing Sector ↗

April 07, 2026

Robert Half provides staffing and consulting services to global clients across accounting, finance, IT, legal, and creative sectors.

Via The Motley Fool

Topics Regulatory Compliance

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

April 07, 2026

From Johnson & Johnson

Via Business Wire

You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500. ↗

April 07, 2026

Could this player be heading into a new era of growth?

Via The Motley Fool

Topics Artificial Intelligence Economy Stocks

Robotic Revolution in the Electrophysiology Lab: FDA Clears Stereotaxis Synchrony System

April 06, 2026

ST. LOUIS – April 6, 2026 – In a milestone that signals a paradigm shift for cardiac care, Stereotaxis (NYSE American: STXS) has received FDA 510(k) clearance for its Synchrony™ System. The approval...

Via MarketMinute

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.